Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
topepegfilgrastim
- Development stage
- Unknown
- Lead developer
- Xiamen Tebao Biological Engineering
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Injection
01
Overview
Topepegfilgrastim is a long-acting PEGylated recombinant granulocyte colony-stimulating factor (G-CSF) analog being developed by Xiamen Tebao Biological Engineering (Amoytop Biotech). It functions as an agonist of the G-CSF receptor (CSF3R), stimulating the proliferation, differentiation, and activation of neutrophils. The drug is specifically designed for the prevention of febrile neutropenia in patients undergoing myelosuppressive chemotherapy. By utilizing PEGylation technology to modify the recombinant protein, topepegfilgrastim achieves a prolonged half-life, allowing for reduced dosing frequency compared to first-generation G-CSF treatments. It is currently in Phase 1 clinical development, representing a distinct pipeline candidate from the company's previously approved G-CSF product, Telpegfilgrastim.
- Other names
- 拓培非格司非坦Topepegfilgrastim Injection拓培非格司非坦注射液
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on topepegfilgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on topepegfilgrastim.